Garcia Reboll L, Jiménez Cruz J F, Montserrat Monfort J J, Sánchez Plumed J, Pallardo L
Servicio de Urología, Hospital Universitario La Fe, Valencia.
Actas Urol Esp. 1996 Sep;20(8):690-6.
Though hypogonadism is part of the clinical picture of chronic renal failure, its etiology remains unknown. Because of the consequences it may have on the prostate gland, it was decided to conduct a prospective evaluation on its influence on prostatic signs and symptoms and glandular growth in a group of patients with chronic renal failure undergoing dialysis and a second group with renal transplantation. To this end, the presence of symptoms was assessed in 78 subjects over 50 years of age: 22 healthy controls (group C) (28.2%), 28 in haemodialysis (Group HD) (35.0%) and 28 with renal transplantation (Group RT) (35.9%). All subjects were aged between 53 and 80 years (mean 58.29 +/- 5.45). Determination of degree of prostatism was done by the International Prostate Symptoms Score (IPSS-S and L), flowmetry, ultrasound postmictional residue, transrectal ultrasound with 3 prostatic diameters (cross-sectional, antero-posterior and longitudinal), prostate weight and plasma levels of PSA, testosterone, FSH, LH, PRL and oestradiol. In 26 of 28 patients in the HD group IPSS-L, flowmetry and post-mictional residue was not assessed as they had no spontaneous miction. There were significant differences in IPSS between C and RT (p = 0.003), Qmax between C and RT (p = 0.009), post-mictional residue between C and RT (p = 0.045), cross-sectional diameter between C and HD (p = 0.036), prostate weight between C and HD (p = 0.001), and between HD and RT (p = 0.001), PSA between C and RT (p = 0.026), FSH between C and HD (p = 0.005), LH between HD and RT (p = 0.020), PRL between HD and RT (p = 0.023), Oestradiol between C and HD (p = 0.032). We conclude that hypogonadism is a factor which, in patients with chronic renal failure and renal transplantation, contributes to prevent prostate growth thus minimizing the symptoms of prostatism.
虽然性腺功能减退是慢性肾衰竭临床表现的一部分，但其病因仍不清楚。鉴于其可能对前列腺产生的影响，决定对一组接受透析的慢性肾衰竭患者以及另一组肾移植患者进行前瞻性评估，以研究性腺功能减退对前列腺体征、症状及腺体生长的影响。为此，对78名50岁以上的受试者进行了症状评估：22名健康对照者（C组）（28.2%），28名血液透析患者（HD组）（35.0%），28名肾移植患者（RT组）（35.9%）。所有受试者年龄在53至80岁之间（平均58.29±5.45）。通过国际前列腺症状评分（IPSS-S和L）、尿流率测定、排尿后残余尿量超声检查、经直肠超声测量前列腺三个直径（横径、前后径和纵径）、前列腺重量以及血浆中前列腺特异性抗原（PSA）、睾酮、促卵泡生成素（FSH）、促黄体生成素（LH）、泌乳素（PRL）和雌二醇水平来确定前列腺增生程度。HD组28例患者中有26例因无自主排尿而未评估IPSS-L、尿流率和排尿后残余尿量。C组和RT组在IPSS上有显著差异（p = 0.003），C组和RT组在最大尿流率（Qmax）上有显著差异（p = 0.009），C组和RT组在排尿后残余尿量上有显著差异（p = 0.045），C组和HD组在横径上有显著差异（p = 0.036），C组和HD组在前列腺重量上有显著差异（p = 0.001），HD组和RT组在前列腺重量上有显著差异（p = 0.001），C组和RT组在PSA上有显著差异（p = 0.026），C组和HD组在FSH上有显著差异（p = 0.005），HD组和RT组在LH上有显著差异（p = 0.020），HD组和RT组在PRL上有显著差异（p = 0.023），C组和HD组在雌二醇上有显著差异（p = 0.032）。我们得出结论，性腺功能减退是一个因素，在慢性肾衰竭和肾移植患者中，它有助于抑制前列腺生长，从而将前列腺增生症状降至最低。
